Editorial Archives - Page 56 of 123 - ExecEdge

Ascentage Secures Third Breakthrough Therapy for Ph+ ALL Treatment

Ascentage Secures Third Breakthrough Therapy for Ph+ ALL Treatment

By Daniella Parra Ascentage Pharma (NASDAQ: AAPG; HKEX) said that its drug Olverembatinib is the first China-approved third-generation BCR-ABL inhibitor, and has been approved for certain chronic myeloid leukemia (CML) indications and included in China’s National Reimbursement Drug List. Olverembatinib,...

Nanox.ARC Imaging System Granted Certification in EU

Nanox.ARC Imaging System Granted Certification in EU

By Karen Roman Medical tech company Nano-X Imaging Ltd. (Nasdaq: NNOX) said Nanox.ARC, its digital multi-source 3D tomosynthesis imaging system, received CE mark certification in the European market. Nanox.ARC also has FDA clearance for general use in the U.S. and...

On Q4 Gross Profit Soars 40%; Strong FY25 Outlook

On Q4 Gross Profit Soars 40%; Strong FY25 Outlook

By Karen Roman On Holding AG (NYSE: ONON) said fourth quarter adjusted diluted earnings per share increased to CHF 0.33 from CHF (0.05) the year prior, surpassing analysts’ expectations and raising its market price per share around 5%. Gross profit...

FIGS Q4 Revenue Up 5% to $151.8 million

FIGS Q4 Revenue Up 5% to $151.8 million

By Karen Roman Healthcare apparel brand FIGS, Inc. (NYSE: FIGS) said fourth quarter net revenue increased 4.8% to $151.8 million compared to the year prior, beating analysts’ expectations. Adjusted EBITDA was $21.1 million and adjusted EBITDA margin was 13.9%, compared...

Olo Q4 Revenue Up 21%, Beats Estimates

Olo Q4 Revenue Up 21%, Beats Estimates

By Karen Roman Restaurant technology provider Olo Inc. (NYSE: OLO) said fourth-quarter revenue increased 21% to $76.1 million year-over-year, beating analysts’ estimates. Gross profit grew 11% to reach $40.3 million, while non-GAAP net income was $11.3 million, or $0.06 per...

Input your search keywords and press Enter.